Our unique approach to developing diagnostics

Our unique approach to identifying disease signatures and developing diagnostics has three powerful components: population-scale serum samples, proprietary analytical technologies, and deidentified electronic health records that correspond with the serum samples. We have applied our technology in our Israeli multi-OMICS serum screening study to create the world’s largest and most comprehensive liquid-chromatography mass-spectrometry (LC-MS) metabolomics dataset. We are also expanding our datasets in lipidomics and proteomics.

Proprietary analytical technologies (Metabolomics, Lipidomics, Proteomics)

Our high-throughput cost-effective multi-omics approach utilizes LC-MS to evaluate tens of thousands of biomarker molecules per sample, in a matter of minutes.

Population-scale serum samples (>500,000)

Through unique partnerships, including with a leading Israeli HMO serving millions of people, we receive de-identified samples daily for multi-OMICS analysis.

Electronic Health Records (EHRs)

Serum samples are associated with de-identified prospective EHR data, supporting the development of novel diagnostic signatures for diverse diseases.


High diagnostic performance:

Multi-OMICS analysis enabling diagnostic signatures combining diverse molecules.

High quality assurance:

Uniform and consistent cases and control sample collection and processing, preventing technical confounders

Suitable for population screening:

Based on high-throughput cost-effective mass-spectrometry

Robust diagnostic signatures:

  • Generated based on hundreds of thousands of samples collected from the general population across hundreds of clinics - simulating real world diagnostic screening programs
  • Analyzed samples from patients with diverse matched co-morbidities
  • Samples collected prior to diagnosis, preventing artifacts due to treatment and/or change in lifestyle